Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis

Stopped early · Phase 2/Phase 3

Conditions studied: Dermatomyositis

In brief

Juvenile dermatomyositis (JDMS) is one of the most serious of the childhood rheumatic diseases. The theory behind this trial is that early introduction of etanercept or methotrexate will prove to be effective in the treatment of JDMS. Pretreatment muscle biopsies, we believe there will be abnormalities in the blood vessels that will be correlated with worse physical strength and daily functional ability. The long-term goal is to improve the treatment of this serious childhood onset rheumatic disease and to better understand the pathogenic mechanism for the development of the vasculopathy (disorder of blood vessels) of JDMS. Identification of the specific mechanism of the vasculopathy may allow for the rational introduction of biologic treatments focused on vascular growth.

Key facts

Study ID
NCT00035958
Run by
Children's Hospital Medical Center, Cincinnati
People needed
75
Starts
2002-08-01
Expected to finish
2002-08-01
Last updated by the study team
2013-08-01

Who can join

Age: 4 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.